Europe Cancer Monoclonal Antibodies Market Report
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Europe</strong> <strong>Cancer</strong> <strong>Monoclonal</strong> <strong>Antibodies</strong> <strong>Market</strong><br />
The <strong>Europe</strong> <strong>Cancer</strong> <strong>Monoclonal</strong> <strong>Antibodies</strong> <strong>Market</strong> is a USD 7 billion market in 2015<br />
and is estimated to reach USD 11.8 billion by 2020 with a growth rate of 10.9%.<br />
<strong>Cancer</strong> is the cause of death for millions of people around the world. <strong>Cancer</strong>, which<br />
starts from a single cell is gradually transformed to other cells by genetically<br />
transforming a normal cell to tumour. The dramatic increase in the size of cancer<br />
patients has made the pharmaceutical firms to shift their focus towards monoclonal<br />
antibodies market. The traditional way of treating cancer includes usage of drugs like<br />
chemotherapy agents which has adverse side effects. This prompted the usage of<br />
monoclonal antibodies to treat cancer.<br />
Recent years have seen the emergence of monoclonal antibodies owing to its<br />
potentiality to offer less toxic and highly efficient alternatives to the patients. The<br />
antibodies has the ability to treat many diseases related to inflammatory,<br />
autoimmune and especially cancer. The antibodies comprises of identical cells which<br />
are clones of a single parent cells and directed towards specific targets cells. Thus<br />
monoclonal antibodies due to its specificity to target only cancer cell leaving behind<br />
the healthy one, can be a more efficient way of treating cancer than chemotherapies<br />
or drugs.<br />
Increased prevalence of cancer disease is the primary driver for the market. It has led<br />
many pharmaceutical companies to invest heavily in monoclonal antibodies due to<br />
its customizable nature of attacking only the cancer cell. The other drivers for the<br />
market include increasing investments in R&D of genomic studies, advancements in<br />
target gene selection and genetic sequencing and specificity of antibodies to target<br />
only the cancer cells. There are also hurdles prevailing for the monoclonal antibodies<br />
market like high costs of development, strict guidelines by the governments, longer<br />
periods required for clinical trials and research & development.<br />
<strong>Market</strong> Segmentation<br />
By Application<br />
o Liver<br />
o Breast<br />
o Brain<br />
o Blood<br />
o Hodgkins and Non-Hodgkins lymphoma<br />
o Colorectal<br />
o Leukaemia<br />
o Others<br />
By Type<br />
o Murine <strong>Antibodies</strong><br />
+1 888-702-9626 | www.marketdataforecast.com | contact@marketdataforecast.com
Change language